Kwality Pharmaceuticals’ shares surged over 20% in intraday trade following a robust first quarter, with net profit more than doubling and revenue climbing significantly, signalling strong momentum in the company’s growth trajectory.
Kwality Pharmaceuticals’ shares climbed sharply after the drugmaker reported a more than doubling in first-quarter net profit, extending a run of gains that has already made the stock one of the better performers in the Indian market this year. The shares were changing hands at Rs 3,134 on the NSE around midday, up from the previous close of Rs 2,611.80, after rising more than 20% in intraday trade.
The company said consolidated net profit for the June quarter increased to Rs 25.6 crore from Rs 11.9 crore a year earlier. Revenue from operations rose 45.7% to Rs 162 crore from Rs 112 crore, while earnings before interest, tax, depreciation and amortisation jumped 69.1% to Rs 41.1 crore. That pushed the EBITDA margin up to 25.3% from 21.8% in the same quarter last year.
The latest numbers follow a sequence of strong results in earlier quarters. Business Standard reported that net profit rose 87.69% year on year to Rs 16.01 crore in the December 2025 quarter, with sales up 46.24% and operating margin improving to 24.26%. In the March 2026 quarter, profit increased 74.60% to Rs 25.30 crore as revenue climbed 35.81% and margin edged higher again.
The stock has been under close watch since the start of 2026, with NDTV Profit reporting that it had already gained more than 85% before the latest jump. It has traded in a 52-week range of Rs 1,561 to Rs 3,134.10 and carried a market capitalisation of about Rs 3,252 crore at the last close. Investors will now be watching whether Kwality can sustain its revenue momentum and hold on to the improved margin profile in coming quarters, especially as Sahi reported the company is targeting more than Rs 650 crore in revenue by fiscal 2027 and an EBITDA margin of 25%.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
